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Summary  “Artificial corneas” have been attempted in 
severe corneal disease for at least 230 years, with largely 
disappointing results until recently. ‘The Boston Kerato-
prosthesis’ (B-Kpro) has been part of this history on and 
off for a half century.  Developed from several previously 
known concepts, it was originally made of PMMA plas-
tics in a collar button design (Type I), to be implanted 
into a corneal graft carrier and then transplanted to the 
patients’ cornea. (A Type II with an additional stem for lid 
penetration is occasionally used in end-stage dry eyes.)
Management and device changes have over the years 
led to marked clinical improvements. Thus, postopera-
tive infections have been drastically reduced by using 
low-dose prophylactic antibiotics. The corneal surface 
has been found to be well protected from evaporative 
damage by a soft contact lens or a conjunctional flap. 
Postoperative tissue melt around the device has been 
markedly reduced by improvement of nutrition from the 
aqueous (perforated back plates) and better anti-inflam-
matory strategies. Titanium alloys can be used for non-
transparent parts to reduce inflammation and increase 
biointegration. Retroprosthesis membranes and retina 
complications have similarly been markedly reduced. 
However, post-operative glaucoma is still a stubborn 
problem that can cause long-term attrition of vision. 
Autoimmune diseases are particularly treacherous and 
B-KPros should not at present be used routinely. About 
12,000 Boston Keratoprostheses have so far been distrib-
uted world-wide. Robust research is presently on-going 
to improve long-term safety, especially for the develop-
ing world.
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Die Boston-Keratoprothese 2014 – Ein Schritt in 
der Entwicklung künstlicher Hornhäute
Zusammenfassung „Künstliche Hornhäute“ stehen seit 
zumindest 230 Jahren in der Behandlung schwerer Horn-
hauterkrankungen mit bis zuletzt meist enttäuschenden 
Ergebnissen im Einsatz. Seit einem halben Jahrhundert 
ist die ‚Boston-Keratoprothese‘ (B-KPro) immer wieder 
Teil dieser Entwicklungen gewesen. Die B-KPro wurde 
aus verschiedenen bekannten Konzepten heraus ent-
wickelt und bestand ursprünglich aus PMMA-Plastiken 
im Kragenknopf-Typ (Typ I), die in den Transplantat-
träger implantiert und schließlich in die Hornhaut der 
Patienten transplantiert wurden. (Ein Typ II mit einem 
zusätzlichen Stiel zur Lidpenetration wird gelegentlich 
bei starkem Sicca-Syndrom verwendet.)
Therapeutische und apparative Veränderungen haben 
in den letzten Jahren zu deutlichen klinischen Verbesse-
rungen geführt. So wurden postoperative Infektionen 
durch den Einsatz von niedrigdosierten prophylak-
tischen Antibiotika tiefgreifend verringert. Weiche Kon-
taktlinsen oder Bindehautflaps dienen heute dem Schutz 
der Hornhautoberfläche vor evaporativen Schädigun-
gen. Postoperative Gewebseinschmelzungen um das 
Instrument wurden durch eine verbesserte Versorgung 
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aus dem Kammerwasser und gezieltere anti-inflam-
matorische Strategien deutlich reduziert. Titanlegier-
ungen können bei nicht-transparenten Bestandteilen 
zur Eindämmung von Entzündungen und Erhöhung 
der Biointegration eingesetzt werden. Ein hartnäckiges 
Problem ist allerdings nach wie vor das postoperative 
Glaukom, das eine langzeitliche Abnahme der Sehkraft 
bewirken kann. Darüber hinaus sind Autoimmuner-
krankungen besonders heimtückisch, sodass B-KPros 
noch nicht in der Routinebehandlung verwendet werden 
sollten. An die 12.000 B-KPros sind bisher weltweit im 
Umlauf. Intensive Forschungen widmen sich der Ver-
besserung der längerfristigen Sicherheit, insbesondere 
in Entwicklungsländern.
Schlüsselwörter Künstliche Hornhaut · Keratoprothese
Introduction
Attempting to restore vision in an eye with severe corneal 
opacities by implanting a window of transparent foreign 
material into the cornea is an obvious concept which has 
attracted skilled surgeons and sharp minds for more than 
2 centuries (for history, see Cardona [19] Dohlman [29] 
Mannis and Dohlman [54]). The problem, however, has 
been in its execution. Complications (infections, glau-
coma, retinal detachments, etc.) have traditionally been 
frequent and severe, often leading to loss of the eye. Not 
until the mid-1900s did prospects improve somewhat 
with the introduction of antibiotics and corticosteroids. 
Also, identification by several investigators of transparent 
and relatively inert plastics (polymethylmethacrylate, 
etc.) for the manufacturing of devices (particularly Stone 
and Herbert [78]), as well as the introduction of better 
surgical techniques at that time, resulted in improved 
keratoprosthesis (KPro) outcomes. Moreover, varied 
KPro designs were presented by a number of investiga-
tors in the early 1950s—virtually all presently used con-
figurations were already suggested at that time (reviewed 
by Cardona [19]).
In spite of these developments, skepsis against the 
routine use of KPros was still widespread for decades—
understandably, due to the still high rate of complica-
tions. In Boston, our first efforts in this difficult field were 
made in the mid-1960s (Dohlman et al. [32]) but it was 
not until 1989 that we gave the subject top priority. Food 
and Drug Administration granted marketing clearance 
for our Boston Keratoprosthesis (B-KPro) in 1992. Since 
then, faculty members, plus generations of fellows at the 
Massachusetts Eye and Ear Infirmary (MEEI)/Harvard 
Medical School have continued to try to create somewhat 
of a scientific basis for future refinements. Some metrics: 
36 B-KPros were implanted 1965–1973 (C.H.D.), about 
420 during 1990–2010 (C.H.D.), and another about 500 
were implanted by other MEEI colleagues 2000—pres-
ent. Among the above-mentioned 420 cases 80 % were of 
Type I and the rest Type II (see below). Worldwide about 
11,000 B-KPros have now been used in over 50 countries. 
Close to 300 publications from several groups have been 
published on the subject (Boston Keratoprosthesis Bibli-
ography, 2013, 2014). The steps in the development of the 
B-KPro will now be summarized here.
Design and materials
After trials with radically different KPro designs, we set-
tled on a collar button-shaped polymethylmethacrylate 
(PMMA) device, to be implanted into a carrier corneal 
graft—this combination then transplanted and sutured 
into the patient’s cornea like a standard graft [31] (Fig. 1). 
It was felt that retention was improved by placing the 
haptic (the back plate) totally behind the cornea, rather 
than having it placed in the stroma. Later, large holes in 
the back plate were made to facilitate diffusion of nutri-
ents from the aqueous to the graft keratocytes [42]. Also 
a new threadless design was introduced to better protect 
the graft Descemet’s membrane and endothelium of 
the graft from damage during assembly [34]. The metal 
titanium, which has been widely used elsewhere in the 
body, and had previously been incorporated as intrastro-
mal haptics in KPro devices [45, 51, 55], was adopted by 
us as back plate in 2005 (Fig. 2). We have found this mate-
rial (actually an alloy, medical grade 23, consisting of 
titanium 90 %, aluminium 6 %, and vanadium 4 %) to be 
better tolerated by corneal tissues than PMMA, in vitro 
as well as in vivo [4, 79]. The somewhat shiny appearance 
of the metal can be cosmetically troublesome (Fig. 2) but 
it can be dampened by electrolysis, creating a blue or 
brown surface [61] (Tinted soft contact lenses can also be 
cosmetically helpful). The diameter of the titanium back 
plate is normally chosen as 8.5, or 7.0 mm, but in selected 
cases, a larger diameter (9.5  mm) has been found to 
clamp the graft wound better and may reduce the inci-
dence of retroprosthesis membranes (RPMs), anterior 
synechia formation, and possibly even glaucoma [25], 
although the subject is still controversial. Recent experi-
ments have shown that coating also the stem of the 
B-KPro with titanium strongly improves tissue adhesion, 
most likely making passage of bacteria or fungi into the 
eye less likely [72]. Coating the stem with a thin, inert 
antimicrobial substance may have similar effect [11].
Another design, labeled B-KPro II (Fig.  1) has an 
added anterior nub to protrude between closed lids 
or through the upper lid—similar to lid arrangement 
used by Strampelli (1963) and DeVoe [19]. This device is 
reserved for the most desperate of corneal diseases such 
as totally dry eyes from autoimmune diseases or chemi-
cal burns [16, 59, 75].
Carrier tissue
The Boston KPro requires a carrier corneal graft—with-
out which surgery becomes forbiddingly complex [31]. In 
some cases, the patient’s own cornea (autograft) can be 
used, trephined out, and assembled with the B-KPro on 
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Prognostic categories
Rapidly, it became clear to us that the prognosis for a suc-
cessful B-KPro outcome varied markedly between pre-
operative disease categories. This observation had been 
made previously to a degree in various settings [37]. Still, 
we scrutinized numerically the outcome in various pre-
operative eye or systemic disease categories, with quite 
revealing results [82]; the small but important group of 
presumed autoimmune diseases (Stevens–Johnson syn-
drome, mucous membrane pemphigoid, graft-vs-host 
disease, atopy, uveitis, etc.) had by far the worst outcome, 
with chemical burns more favorable (Fig. 3). In the large 
group of non-autoimmune corneal diseases, such as dys-
trophies, post-infections graft failures, etc., the B-KPro 
did rather well. The common adverse denominator was 
clearly the degree of preoperative chronic inflammation. 
Subsequent outcome studies for subgroups followed for: 
Herpes simplex keratitis [48], Herpes zoster [63], aniridia 
[1], epithelial downgrowth into the anterior chamber 
[73], etc.—all showed quite good retention [22]. It is 
clearly in this general category of relatively low degree of 
inflammation that the B-KPro does the most good, with 
a side table before being sutured back into the patient’s 
eye [5]. Most often, however, Eye Bank allografts are used 
which incur heavy cost due to the necessary testing and 
administration. Allogenous corneas have been modified 
to reduce antigenicity or improve storage and shipment. 
Thus, it has been shown that frozen (thus decellularized) 
corneas are well tolerated as B-KPro carriers [67]. Like-
wise, several centers have used γ-radiated corneas with 
success, again facilitating storage and shipment [2, 39]. 
In order to reduce postoperative tissue melt, carrier cor-
neas have also been cross-linked with ultraviolet (UV) 
light which has been shown to convey considerable resis-
tance to enzymatic digestion in vitro [8]. Clinically such 
corneas have been employed as carriers with success [47, 
69]. For the developing world, however, less expensive 
alternatives must be sought when autografts are not pos-
sible; experiments with γ-radiated porcine xenografts, 
supplemented with a total conjunctival flap, and other 
possibilities are presently ongoing [26].
Fig. 2 Boston keratoprosthe-
sis Type I with titanium back 
plate
 
Fig. 1 a Assembly of Boston 
keratoprosthesis (B-KPro) 
Type I. In another modification 
the locking ring is eliminated 
and the back plate snaps di-
rectly onto the stem. b B-KPro 
Type I with polymethylmeth-
acrylate (PMMA) back plate. c 
B-KPro Type I and II. d B-KPro 
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predominant, fungal keratitis is common. In a B-KPro 
eye, fungal colonization is easily missed clinically and a 
prophylactic regimen against the common fungi would 
be desirable. The search for an inexpensive practical and 
effective such regimen is presently underway.
Necrosis, tissue melt
Necrosis and melt of the tissue around the KPro can lead 
to aqueous leak, infection, or extrusion, and this com-
plication is more prevalent in patients with autoimmune 
diseases [82]. In these patients the level of matrix metal-
loproteinases in tears is elevated [9]. Fortunately, the 
incidence of tissue melt became markedly reduced with 
the introduction of the aforementioned perforated back 
plate, improving tissue nutrition for the carrier graft [42]. 
Anti-collagenase medication such as 1.0 % suspension of 
medroxyprogesterone [29, 44, 49] two to three times daily, 
and topical (0.1 %) or systemic doxycycline are definitely 
helpful. Dramatic effects have been seen following sys-
temic infusion of the tumor necrosis factor-alpha (TNF-α) 
inhibitor infliximab in a small group of cases of B-KPro in 
rheumatoid arthritis and Stevens–Johnson syndrome [32, 
35]. Topical infliximab is now being evaluated in similar 
situations [70]. Also as mentioned above, cross-linked 
carrier corneas may prevent postoperative melt.
Glaucoma
After corneal complications such as melt and infection 
have gradually been brought under reasonable con-
trol, it is clear that glaucoma has emerged as the great-
est obstacle to long-term success of the KPro [56]. Most 
patients being evaluated for KPro, in our studies as well 
as in others, have had glaucoma prior to B-KPro surgery 
[68]. Subsequently, the glaucoma often worsens, as has 
been measured by changes in cup/disc ratio and visual 
fields [24]. In a recent example from the field, 90 % of the 
patients in a Thai study experienced prompt improve-
ment of vision with B-KPro surgery, compared with 
preoperatively, but this percentage decreased to 55 % 
after 6 years. The primary reason for the visual decline 
was glaucoma—no glaucoma drainage device had been 
implanted before or simultaneously with the B-KPro [50]. 
We feel that an early glaucoma drainage device, specifi-
the possible exception of pediatric KPro which remains 
challenging [7]. These outcomes have been well docu-
mented also from other institutions in numerous studies 
(Boston Keratoprosthesis Bibliography, 2013, []). After 
one standard corneal graft failure, it is often the safest 
to implant a B-KPro instead of doing a repeat graft [52]. 
Also in some cases of severe corneal blindness with poor 
prognosis for keratoplasty, there is justification in using a 
B-KPro as a primary procedure instead of starting with a 
standard graft [20].
As mentioned, the autoimmune disease category 
turned out to be the most difficult subgroup (see below). 
This has led us to conclude that B-KPros presently should 
not be implanted routinely in autoimmune diseases and 
that work on this category should for the moment be 
restricted to carefully structured studies in academic set-
tings. Research to improve outcome in this group is pres-
ently intense.
The various categories of complications will now be 
summarized here.
Infections, prophylaxis
Endophthalmitis, usually from gram-positive bacteria, 
frequently results in total vision loss and it is one of the 
most feared complications after a KPro. However, since 
1990 we have gradually shown that surprisingly low 
doses of daily antibiotics have a very strong prophylactic 
effect [12, 27, 57]. Over the years we have come to pre-
fer the combination of Polymyxin B and trimethoprim 
(PolytrimTM drops, effective against both gram-positive 
and most gram-negative bacteria), and titration has 
shown that one drop a day gives sufficient coverage in 
nonautoimmune cases [12]. In the most critical situa-
tions (autoimmune, only eyes, etc.), we add vancomy-
cin (1.4 %) once or twice daily [38]. Compliance with 
the daily regimen is of course important and cannot be 
taken for granted. Therefore, the recent development of a 
soft contact lens that can elute antibiotics at an even rate 
(zero order release) for a month, promises to be quite 
useful in the future [21]. Looking back, the introduction 
of a daily low-dose antibiotics prophylaxis for life has 
been the most important step toward long-term safety of 
penetrating artificial corneas.
In large parts of the world, especially where the cli-
mate is hot and humid and where agricultural work is 
Fig. 3 Acid burn pre- and 
postoperatively. Boston 
Keratoprosthesis Type I since 
15 years. Vision 20/40
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in the presence of a cloudy cornea, such inflammation 
is difficult to diagnose preoperatively. Such a situation is 
likely to get worse with every subsequent surgical proce-
dure, including a B-KPro. It can result in RPM, vitreous 
opacities, cystoid macular edema, epiretinal membrane, 
or—worst of all—a retinal detachment, which has a poor 
record of repair [40, 46, 65]. Again, autoimmune disease 
is the leading risk factor. A vision-reducing RPM used to 
be the most common complication after B-KPro [29]. In 
most cases, the membrane can be sufficiently opened 
by cautious yttrium aluminium garnet (YAG) laser [10] 
but when dense and vascularized, total reoperation with 
open-sky membranectomy seems to be the least trau-
matic. The incidence of RPM has been steadily falling 
and, as mentioned above, using a back plate of titanium 
rather than PMMA reduces the rate of membrane forma-
tion [79]. In addition, costicosteroids, TNF-α inhibitors, 
medroxyprogesterone, doxycycline, etc. can be helpful 
in bringing the often subtle inflammation under con-
trol. Ongoing laboratory experiments with a miniature 
Boston-type KPro, implanted into mice corneas and fol-
lowed by quantitative analysis of inflammatory cytokines 
and cells, promise to clarify the mechanisms [23].
“Sterile vitritis” is a peculiar form of uveitis/endo-
phthalmitis that is classically characterized by very sud-
den (often overnight), massive vitreous opacities, but 
which in most cases results in eventual clearing and 
restored vision [41, 58, 64]. It may be triggered by YAG 
laser treatment, eye rubbing, or other factors. Cortico-
steroids (topical, subtenon) expedite resolution. The 
incidence seems to be around 5–15 % [40, 41]. The main 
problem with sterile vitritis is the difficulty of being cer-
tain early in the process that a bacterial endophthalmitis 
is not present.
Ocular surface protection
The introduction of around-the-clock wear of large soft 
contact lenses represented a major step toward B-KPro 
safety [33]. For instance, a 16  mm KonturTM lens is well 
tolerated and distributes evaporative forces well, protect-
ing the surface. Some lenses cannot be retained [43] and a 
few patients develop central deposits from poor blinking 
[14], but the majority do well. If deposits occur, replace-
ment with a hybrid lens with a hard center usually solves 
the problem. Tinted or painted lenses with a clear center 
are useful to reduce glare or to improve cosmetics [76].
Under circumstances when soft contact lens wear is 
not expected to be feasible due to cost or poor retention, a 
total conjunctival flap (if possible to mobilize) with a cen-
tral opening can be a satisfactory substitute. A total, loose 
flap from the temporal side might be drawn over the fully 
de-epithelialized cornea and anchored at the limbus with 
fine nylon sutures [3]. The flap results in building up tissue 
peripheral to the anterior plate of the B-KPro, preventing 
tissue melt and contributing to good retention and safety 
even in the absence of a soft lens. Thus, a conjunctival flap 
works well but adds to surgery time.
cally a valved shunt (Ahmed), is very helpful in retarding 
further deterioration and should be routinely employed 
in all cases of B-KPro surgery when glaucoma has been 
documented preoperatively. Still, dangerous pressure 
rises can occur later over the years and new shunt prin-
ciples need to be introduced to fit the B-KPro situation. 
One device, based on ferromagnetic principles and 
responding to both opening pressure and closing pres-
sure, presently is being developed and tested [60]. In the 
severest cicatrizing situations, aqueous may have to be 
shunted to lower lid fornix or to one of the sinuses, thus 
to atmospheric pressure outside the eye [36]. This prin-
ciple is surprisingly safe against infection and it might 
also be applicable in extremely dry eyes where aqueous 
shunted to the lower lid fornix can serve as “tears” [30]. 
Also, cyclophotocoagulation in some form is often used 
after B-KPro [66].
Managing glaucoma in a B-KPro eye is particularly 
challenging since it is difficult to determine the intra-
ocular pressure. Indentation tonometry is not reliable 
due to the back plate size and rigidity and therefore only 
gross estimation with finger palpation remains presently 
available. However, it has recently been shown that a 
small German-made ring-shaped pressure transducer 
(ImplandataTM), encapsulated in silicone rubber, can be 
implanted safely behind the iris, and the pressure be reg-
istered by radio waves with a recording device from the 
outside [78]. Promising clinical trials are currently under 
way [54].
The development of glaucoma after B-KPro surgery—
actually after any corneal surgery—raises questions 
about the pathophysiology of the optic nerve damage. In 
many cases of B-KPro the intraocular pressure remains 
normal postoperatively but the optic nerve head can 
still gradually become cupped and pale. This sequence 
of events is particularly obvious after chemical burn, 
especially alkali burns [16]. Subsequent investigations 
showed absence of direct diffusion of alkali to the retina 
level and instead it seems that inflammatory cytokines 
are generated by the burn in the anterior segment and 
rapidly diffuse posteriorly to cause ganglion cell apopto-
sis and other cell damage. TNF-α is probably one such 
inflammatory mediator because intraperitoneal injec-
tion of its inhibitor infliximab soon after corneal burn in 
mice, strongly protects the ganglion cells from apopto-
sis [17]. This raises the future possibility of being able to 
protect chemical burn patients from posterior segment 
damage by promptly infusing infliximab or similar inhib-
itor while the patient receives ocular lavage in the emer-
gency room. Later, in a less-inflamed stage, the cornea 
can be implanted with a B-KPro with high likelihood of 
success [16].
Intraocular inflammation, sterile vitritis, retinal 
detachment
Many patients with severe corneal damage may also 
have low-grade inflammation prior to KPro surgery but, 
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happy to see that the rate of postoperative endophthal-
mitis has decreased about 10-fold over 2 decades—due 
to prophylactic antibiotics. Corneal melt around the 
device has likewise decreased by about a log unit to 
about 3 % over the first 17 postoperative months [22]. 
The retroprosthetic membrane is clearly diminish-
ing in frequency and may be on its way out. However, 
while the Boston KPro of 2014 has made great improve-
ments over the past 50 years, we still have a road to travel 
until we have a truly effective, inexpensive and, most 
importantly, a long-term safe procedure with low rate 
of postoperative inflammation, glaucoma, or retinal 
detachment even for the most severe cases, in resource-
poor countries.
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